Eiger BioPharmaceuticals (EIGR) Reports Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy
Tweet Send to a Friend
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive data with Pegylated Interferon Lambda (Lambda) in the Phase 2 LIMT HDV ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
